Tabercarpamine J






Names

    • Tabercarpamine J

Attributes

  • Canonical SMILES

    C[C@@](O)([H])[C@]1([H])C(NCC2)[C@]3(C(OC)=O)C4=C2C5=CC=CC=C5N4C(C(C1)C3)=C

  • InChI

    InChI=1S/C22H26N2O3/c1-12-14-10-17(13(2)25)19-22(11-14,21(26)27-3)20-16(8-9-23-19)15-6-4-5-7-18(15)24(12)20/h4-7,13-14,17,19,23,25H,1,8-11H2,2-3H3/t13-,14?,17+,19?,22-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 63.489999999999995
  • #RotBonds: 2
  • MW: 366.4610000000002
  • HBD: 2
  • HBA: 5
  • logP: 2.4577
  • Chemical Formula: C22H26N2O3


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Tabercarpamines A-J, apoptosis-inducing indole alkaloids from the leaves of Tabernaemontana corymbosa. J Nat Prod, 2014 (PMID 24773071).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Growth inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.65
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.77
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -1.89
    Distribution Blood-Brain Barrier (Central Nervous System) -2.14
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.06
    Plasma Protein Binding 54.53
    Steady State Volume of Distribution 4.11
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 9.29
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Toxic
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 0.9
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.17
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 7.64
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -10.25
    Rat (Acute) 3.16
    Rat (Chronic Oral) 1.78
    Fathead Minnow 4.02
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 430.31
    Hydration Free Energy -6.57
    Log(D) at pH=7.4 2.78
    Log(P) 1.73
    Log S -2.81
    Log(Vapor Pressure) -8.41
    Melting Point 183.65
    pKa Acid 10.08
    pKa Basic 7.01